Simplex Trading
GLUE icon

Simplex Trading’s Monte Rosa Therapeutics GLUE Stock Holding History

Simplex Trading’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$165K Sell
6,800
-1,100
-14% -$20.8K ﹤0.01% 4958
2026
Q1 		$130K Sell
7,900
-65,600
-89% -$1.25M ﹤0.01% 4783
2025
Q4 		$1.15M Sell
73,500
-85,600
-54% -$1.15M ﹤0.01% 2495
2025
Q3 		$1.18M Buy
159,100
+152,900
+2,466% +$810K ﹤0.01% 2889
2025
Q2 		$27K Sell
6,200
-8,600
-58% -$38.4K ﹤0.01% 6496
2025
Q1 		$68K Buy
14,800
+12,700
+605% +$77.9K ﹤0.01% 5475
2024
Q4 		$14K Buy
+2,100
New +$15.8K ﹤0.01% 6945
2024
Q3 		– Sell
-3,400
Closed -$12K – 8887
2024
Q2 		$12K Buy
3,400
+2,300
+209% +$11.7K ﹤0.01% 7288
2024
Q1 		$7K Sell
1,100
-13,500
-92% -$80.1K ﹤0.01% 7825
2023
Q4 		$82K Buy
+14,600
New +$57.3K ﹤0.01% 5582

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Simplex Trading's GLUE Position: Q2 2026 in Review

Simplex Trading sold out of Monte Rosa Therapeutics (GLUE) in Q2 2026, closing a stake of 14,710 shares — an estimated $278K sold.

Simplex Trading first reported a position in GLUE in Q3 2023 and held it in 6 quarters. The position peaked at $551K in Q4 2025. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Simplex Trading reported no remaining Monte Rosa Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Simplex Trading sold 14,710 Monte Rosa Therapeutics shares in Q2 2026, an estimated $278K.
  • Simplex Trading first reported a position in Monte Rosa Therapeutics in Q3 2023 and held it in 6 quarters.
  • Simplex Trading's Monte Rosa Therapeutics position peaked at $551K in Q4 2025.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.